| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10763172 | Biochemical and Biophysical Research Communications | 2011 | 6 Pages |
Abstract
⺠Trastuzumab (Herceptin®) and the rat ERBB2/HER2/NEU antibody elevate p53 protein levels, enhances apoptosis, increases cleaved caspase-3 levels and diminishes cardiac function. ⺠The adverse cardiac events observed with trastuzumab may stem from its negative regulation of MDM2 events which impairs p53 degradation resultantly promoting apoptosis leading to cardiac dysfunction. ⺠These observations suggest that anticancer agents that inhibit MDM2 and its downstream actions may curb tumor progression at the expense of increasing cardiac stress.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Krishna K. Singh, Praphulla C. Shukla, Adrian Quan, Fina Lovren, Yi Pan, Jesse I. Wolfstadt, Milan Gupta, Mohammed Al-Omran, Howard Leong-Poi, Hwee Teoh, Subodh Verma,